Retatrutide, an investigational triple hormone receptor agonist that has drawn attention for its weight-loss signal, now has its first peer-reviewed phase 3 result in type 2 diabetes. The drug is not approved by any regulator for diabetes — or for any other use — and is not available by prescription.
TRANSCEND-T2D-1 was a 40-week, double-blind, randomised, placebo-controlled trial run at 48 sites in the USA, Mexico, and India, enrolling adults whose diabetes was inadequately controlled by diet and exercise alone (Lancet, DOI 10.1016/S0140-6736(26)00967-0). Of 537 participants randomised 1:1:1:1, 134 received retatrutide 4 mg, 133 received 9 mg, 136 received 12 mg, and 134 received placebo, all by once-weekly injection. Baseline mean HbA1c was 7.9% and mean BMI was 35.8 kg/m².
Who was studied — a narrow, drug-naive group
This was not a typical clinic population. Per the ClinicalTrials.gov registry, eligibility was restricted to adults with an HbA1c of 7.0–9.5% who were insulin-naive and had taken no oral or injectable antihyperglycaemic medication for at least 90 days before screening, with a BMI of 23.0 kg/m² or higher (NCT06354660). In other words, these were people with relatively early, untreated type 2 diabetes — mean diabetes duration was just 2.5 years — managing on diet and exercise alone. The results say nothing about people already on metformin, other agents, or insulin, or about longer-standing or more-advanced disease.
What the trial showed
On the primary endpoint — change in HbA1c at week 40 — retatrutide cut HbA1c by 1.69%, 1.86%, and 1.94% across the three doses, versus 0.81% with placebo. That translated to placebo-adjusted reductions of 0.88% (95% CI −1.18 to −0.59), 1.04% (−1.32 to −0.76), and 1.12% (−1.39 to −0.85), all p<0.0001.
Weight loss was a SECONDARY endpoint: bodyweight fell 11.5%, 13.9%, and 15.3% across doses, against 2.6% with placebo — a notable signal, but not the trial’s primary outcome and not an approved use.
Safety, exclusions, and known limitations
The most frequent adverse events were generally mild-to-moderate gastrointestinal events that subsided over time. Adverse events led 2–5% of retatrutide-treated patients to discontinue, versus 0% of placebo-treated patients; no participant had severe hypoglycaemia. Two patients died, both in the 4 mg group, and investigators judged both deaths unrelated to study drug.
The trial deliberately excluded people who carry the highest safety risks for this drug class, so the favourable safety picture should be read with those exclusions in mind. Per the registry, the study barred anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), a history of acute or chronic pancreatitis, severe hypoglycaemia within the prior 6 months, NYHA class IV heart failure, an acute myocardial infarction, stroke, or heart-failure hospitalisation within 90 days, or any lifetime history of a suicide attempt. The MTC/MEN2 exclusion mirrors the boxed-warning-class caution carried by other incretin (GLP-1) agonists, which are contraindicated in people with that history; this remains a known limitation and contraindication consideration for the drug class.
Per the registry, the Eli Lilly–sponsored trial is completed (NCT06354660). Because this was monotherapy in early, drug-naive disease, generalisability to longer-standing or treated diabetes remains to be established.
This is a research result, not medical guidance. Retatrutide is not available by prescription for type 2 diabetes or any other indication, and nothing here should be read as a reason to start, switch to, or ask a clinician to prescribe it. Treatment decisions belong with a patient and their own physician.